In May 2008, febuxostat (Adenuric; Ipsen), an inhibitor of xanthine oxidase, was granted marketing authorization by the European Commission for the treatment of chronic hyperuricaemia in conditions in which urate deposition has occurred, such as gouty arthritis.

In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.

<正>Vismodegib是由瑞士罗氏制药公司驻美国制药厂开发的首个口服的、具有高选择性的Hedgehog信号通路小分子抑制剂,于2012年1月30日经美国食品与药品管理局(FDA)批准上市,商品名为Erivedge。该药适用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转

In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.

ntibody–drug conjugate specific for CD30 approved by the US Food and Drug Administration for the treatment of two types of lymphoma.

Fusion protein that inhibits vascular endothelial growth factor signalling approved in the United States for the treatment of neovascular age-related macular degeneration. In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.

In April 2011, abiraterone acetate (Zytiga; Centocor Ortho Biotech), in combination with prednisone, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.

In November 2010, Custom Anti-Skid White Animal Feed Packaging Bag 50kg (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

In November 2010, Hot DIP Galvanized Ore Mine Support Chain Link Fence Mesh (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

In November 2010, Mc4 Connector for Ja Jinko Trina Canadian Longji Solar Panel (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

In November 2010, Low-Profile Drum Caddy 500kg/1100lb Capacity DC500 (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

In November 2010, Custom Logo Jacquard Polyester Fabric for Handbag Lining (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

In November 2010, Automatic Mold Temperature Controller for Water Type 9kw (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.